CellCentric, a venture-backed epigenetics company, has been awarded £1.15m from the Department of Trade and Industry’s (DTI) technology programme, as part of a £2.3m collaborative programme with three leading research institutions.
Investindustrial sells its remaining stake of 4.12% in the company, fully exiting the investment
Following the deal, CCV Schweiz will be integrated with Concardis Schweiz, which is part of Nets Group
Minority shareholder IMS Capital has also filed for insolvency; Getnow is now seeking new investors
Exit from Rutland Fund III realises a return of 5.7x on the original cost of the investment